{"id":9932,"date":"2025-11-17T06:37:25","date_gmt":"2025-11-17T12:37:25","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9932"},"modified":"2025-12-02T06:51:51","modified_gmt":"2025-12-02T12:51:51","slug":"nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/","title":{"rendered":"Nanoscope Therapeutics fue protagonista de varias presentaciones en Advanced Therapies USA 2025."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"9932\" class=\"elementor elementor-9932\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span class=\"legendSpanClass\">DALLAS<\/span>,\u00a0<span class=\"legendSpanClass\">17 de noviembre de 2025<\/span> \u2014\u00a0<a href=\"http:\/\/Nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy que\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/who-we-are\/samarendra-mohanty\/\" target=\"_blank\" rel=\"nofollow noopener\">Presidente y Director Cient\u00edfico, Samarendra Mohanty, Ph.D.,<\/a>\u00a0y\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/who-we-are\/ramesh-arunji\/\" target=\"_blank\" rel=\"nofollow noopener\">Vicepresidente Ejecutivo de Valor y Acceso, Ramesh Arjunji, Ph.D.,<\/a>\u00a0ser\u00e1n oradores destacados en\u00a0<a href=\"https:\/\/www.terrapinn.com\/congress\/advanced-therapies-usa\/index.stm\" target=\"_blank\" rel=\"nofollow noopener\">Terapias Avanzadas EE. UU. 2025<\/a>. La conferencia se celebrar\u00e1 del 18 al 19 de noviembre en el Centro de Convenciones de Pensilvania, en Filadelfia.<\/p><p>Las presentaciones y el panel de discusi\u00f3n del Dr. Mohanty mostrar\u00e1n la plataforma patentada de Nanoscope, Multi-Characteristic Opsin (MCO), que restaura la visi\u00f3n en pacientes con p\u00e9rdida visual severa debido a retinosis pigmentaria (RP) y enfermedad de Stargardt (SD), ambas afecciones debilitantes sin tratamientos aprobados actualmente. La presentaci\u00f3n del Dr. Arjunji abordar\u00e1 la accesibilidad a las terapias g\u00e9nicas, como la MCO-010 de Nanoscope.\u00a0<\/p><p>A continuaci\u00f3n se detallan las presentaciones y los paneles de discusi\u00f3n:<\/p><p><b>Panel principal:<\/b>\u00a0<i>\u201c<\/i><i>Discurso sobre el estado actual de la industria de las terapias celulares y g\u00e9nicas<\/i><i>\u201c<br class=\"dnr\" \/><\/i><b>Presentador:\u00a0<\/b>Dr. Samarendra Mohanty<br class=\"dnr\" \/><b>Fecha \/ Hora:<\/b>\u00a0Martes, 18 de noviembre de 2025 | 9:05-9:55 a. m. EDT<\/p><p><b>Presentaci\u00f3n:<\/b>\u00a0<i>\u201c<\/i><i>Generaci\u00f3n de evidencia del mundo real y reembolso para la terapia g\u00e9nica.<\/i><i>\u201c<br class=\"dnr\" \/><\/i><b>Presentador:<\/b>\u00a0Dr. Ramesh Arjunji<br class=\"dnr\" \/><b>Pista:<\/b>\u00a0Evidencia, precios y acceso (Pista 3, 120A)<br class=\"dnr\" \/><b>Fecha \/ Hora:<\/b>\u00a0Martes, 18 de noviembre de 2025 | 11:10-11:30 a. m. EDT<\/p><p><b>Presentaci\u00f3n:<\/b>\u00a0<i>\u201c<\/i><i>Terapia g\u00e9nica independiente de la mutaci\u00f3n para enfermedades neurodegenerativas<\/i><i>\u201c<br class=\"dnr\" \/><\/i><b>Presentador:<\/b>\u00a0Dr. Samarendra Mohanty<br class=\"dnr\" \/><b>Pista:<\/b>\u00a0Terapia g\u00e9nica (Pista 5, 120C)<br class=\"dnr\" \/><b>Fecha \/ Hora:<\/b>\u00a0Martes, 18 de noviembre de 2025 | 15:15-15:35 (hora del este de EE. UU.)<\/p><p>\u201cEl Congreso de Terapias Avanzadas es un encuentro fundamental para quienes trabajan para llevar las terapias celulares y g\u00e9nicas desde su concepci\u00f3n hasta su aplicaci\u00f3n cl\u00ednica, y me entusiasma unirme a colegas que comparten un profundo compromiso con la soluci\u00f3n de necesidades m\u00e9dicas no satisfechas\u201d, declar\u00f3 el Dr. Mohanty. \u201cEn Nanoscope, nuestra misi\u00f3n siempre ha sido restaurar una visi\u00f3n significativa a pacientes con enfermedades degenerativas de la retina, independientemente de la causa subyacente, y agradezco la oportunidad de destacar nuestros avances y aprender de quienes trabajan para brindar esperanza y soluciones\u201d.\u201d<\/p><p><b>Acerca de la plataforma MCO<br class=\"dnr\" \/><\/b>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p><p><b>Acerca de Nanoscope Therapeutics<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar una\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>\u00a0En 2025, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de medicamento hu\u00e9rfano de la EMA para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. Se espera que un programa de fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience a finales de 2025. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p><p><b>Contacto:<br class=\"dnr\" \/><\/b>Terap\u00e9utica del nanoscopio<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0Nov. 17, 2025 \u2014\u00a0Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, announced today that\u00a0President and Chief Scientific Officer, Samarendra Mohanty, Ph.D.,\u00a0and\u00a0Executive Vice President of Value and Access, Ramesh Arjunji, Ph.D.,\u00a0will be featured speakers at\u00a0Advanced Therapies USA 2025. [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":8971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9932","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Featured in Multiple Presentations at Advanced Therapies USA 2025 - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Featured in Multiple Presentations at Advanced Therapies USA 2025 - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T12:37:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-02T12:51:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/17\\\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/17\\\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Featured in Multiple Presentations at Advanced Therapies USA 2025\",\"datePublished\":\"2025-11-17T12:37:25+00:00\",\"dateModified\":\"2025-12-02T12:51:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/17\\\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\\\/\"},\"wordCount\":561,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/17\\\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/17\\\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/17\\\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\\\/\",\"name\":\"Nanoscope Therapeutics Featured in Multiple Presentations at Advanced Therapies USA 2025 - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/17\\\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/17\\\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"datePublished\":\"2025-11-17T12:37:25+00:00\",\"dateModified\":\"2025-12-02T12:51:51+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/17\\\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/17\\\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/17\\\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"width\":1200,\"height\":242},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/17\\\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Featured in Multiple Presentations at Advanced Therapies USA 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics estuvo presente en varias presentaciones en Advanced Therapies USA 2025 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Featured in Multiple Presentations at Advanced Therapies USA 2025 - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-11-17T12:37:25+00:00","article_modified_time":"2025-12-02T12:51:51+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Featured in Multiple Presentations at Advanced Therapies USA 2025","datePublished":"2025-11-17T12:37:25+00:00","dateModified":"2025-12-02T12:51:51+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/"},"wordCount":561,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/","url":"https:\/\/nanostherapeutics.com\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/","name":"Nanoscope Therapeutics estuvo presente en varias presentaciones en Advanced Therapies USA 2025 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","datePublished":"2025-11-17T12:37:25+00:00","dateModified":"2025-12-02T12:51:51+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","width":1200,"height":242},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/11\/17\/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Featured in Multiple Presentations at Advanced Therapies USA 2025"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=9932"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9932\/revisions"}],"predecessor-version":[{"id":9936,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9932\/revisions\/9936"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/8971"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=9932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=9932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=9932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}